PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
 
J Virol. 2012 September; 86(18): 9748–9759.
PMCID: PMC3446599

Memory CD8+ T Cells Specific for a Single Immunodominant or Subdominant Determinant Induced by Peptide-Dendritic Cell Immunization Protect from an Acute Lethal Viral Disease

Abstract

The antigens recognized by individual CD8+ T cells are small peptides bound to major histocompatibility complex (MHC) class I molecules. The CD8+ T cell response to a virus is restricted to several peptides, and the magnitudes of the effector as well as memory phases of the response to the individual peptides are generally hierarchical. The peptide eliciting a stronger response is called immunodominant (ID), and those with smaller-magnitude responses are termed subdominant (SD). The relative importance of ID and SD determinants in protective immunity remains to be fully elucidated. We previously showed that multispecific memory CD8+ T cells can protect susceptible mice from mousepox, an acute lethal viral disease. It remained unknown, however, whether CD8+ T cells specific for single ID or SD peptides could be protective. Here, we demonstrate that immunization with dendritic cells pulsed with ID and some but not all SD peptides induces memory CD8+ T cells that are fully capable of protecting susceptible mice from mousepox. Additionally, while natural killer (NK) cells are essential for the natural resistance of nonimmune C57BL/6 (B6) to mousepox, we show that memory CD8+ T cells of single specificity also protect B6 mice depleted of NK cells. This suggests it is feasible to produce effective antiviral CD8+ T cell vaccines using single CD8+ T cell determinants and that NK cells are no longer essential when memory CD8+ T cells are present.

INTRODUCTION

During viral infections, viral proteins are degraded by the proteolytic machinery of the cell into small peptides. Peptides with the appropriate motif and that are 8 to 10 amino acids long bind to major histocompatibility class I (MHC-I) molecules in the endoplasmic reticulum and are transported to the cell surface for presentation to CD8+ T cells, which use clonotypic T cell receptors (TCR) encoded by somatically recombined genes to recognize specific MHC-I-bound peptides, also known as determinants (1). The magnitude of the CD8+ T cell response to the various MHC-I determinants of a virus is generally hierarchical, a phenomenon called T cell immunodominance (59, 60). The determinant that elicits the highest number of CD8+ T cells is termed immunodominant (ID), and those that induce smaller but detectable responses are known as subdominant (SD). Some peptides may bind to MHC-I molecules but be ignored by the CD8+ T cell response. Immunodomination is the result of many interacting factors affecting antigen-presenting cells (APC), such as antigen processing and presentation, and T cells, such as differences in precursor frequency, T cell receptor affinity, competition for activating stimuli, etc. (59, 60).

At the peak of an antiviral response, the frequency of virus-specific CD8+ T cells can be as high as 60 to 80% of the total CD8+ T cells (13, 38). These cells produce effector molecules, such as gamma interferon (IFN-γ), which has antiviral and immunomodulatory effects, and perforin (Prf) and granzyme B (GzB), which kill infected cells through granule exocytosis. If the virus is controlled, ~90% of the antiviral CD8+ T cells die, but some remain as memory CD8+ T cells (38). In the resting state, memory CD8+ T cells do not express effector molecules. However, upon antigen encounter, they rapidly become effectors and proliferate. In this way, they help to quickly control secondary infection by the same or similar viruses. It is thought that memory CD8+ T cells play an important role in vaccine protection, and there is a strong impetus in designing new vaccines that induce protective antiviral CD8+ T cell memory. Therefore, it is of interest to determine the level of protection that can be conferred by memory CD8+ T cells specific for ID or SD determinants during a lethal viral infection.

It has been reported that peptide-dendritic cell (DC) vaccination with a Listeria monocytogenes ID determinant reduced bacterial burden (3). It has also been shown that immunization with recombinant vaccinia virus (VACV) expressing various lymphocytic choriomeningitis virus (LCMV) determinants protected mice from lethal intracranial LCMV challenge infection (28, 29, 56). In addition, the same VACV recombinants (41) and DNA vaccines expressing the LCMV nucleoprotein (NP) containing an ID determinant (34) protected mice from chronic LCMV clone 13 infection administered intravenously (i.v.). Presently, it remains unknown whether memory CD8+ T cells specific for single ID or SD determinants can protect from a lethal acute systemic viral infection that spreads via the lympho-hematogenous route in its natural host.

Natural killer (NK) cells are cells of the innate immune system that are essential for resistance to several primary viral infections (9, 10, 25, 26, 43). Similar to CD8+ T cells, their main effector mechanism are the production of IFN-γ and killing of infected cells by granule exocytosis (5, 7, 18, 22, 32). Different from CD8+ T cells, however, NK cells recognize infected cells using germ line-encoded activating receptors rather than antigen-specific receptors (30). Because NK cells do not need to expand clonotypically, they can contribute to virus control during the first few days of infection, when the adaptive response is still incipient. Because their effector functions overlap, it remains possible that NK cells are no longer required when antiviral memory CD8+ T cells are present at relatively high frequencies; however, this possibility has not been thoroughly explored.

Orthopoxviruses (OPV) are a genus of highly conserved DNA viruses that includes, among others, variola virus, the causative agent of smallpox in humans, VACV, the virus used as the smallpox vaccine, and ectromelia virus (ECTV), the causative agent of mousepox in mice (16). Different from VACV, which is often used as the prototypic OPV, ECTV naturally infects the mouse. When inoculated with as little as 1 PFU in the footpad, its natural route of infection, ECTV causes disease and death in susceptible mouse strains, including BALB/c (H-2d) (54) and B6.D2-(D6Mit149-D6Mit15)/LusJ, a congenic strain of C57BL/6 (B6) that carries the distal portion of chromosome 6 of the susceptible DBA/2J strain, and referred to here as B6.D2-D6 (H-2b) (11, 15). On the other hand, B6 mice are naturally resistant to mousepox but become susceptible if depleted of NK cells before or soon after infection (9, 10, 43).

We have previously shown that memory CD8+ T cells can protect susceptible mice from lethal mousepox (58). Therefore, ECTV infection of susceptible mice serves as a model to understand the mechanisms of CD8+ T cell protective immunity. Work by others has shown that the sequence of the ID H-2 Kb-restricted determinant TSYKFESV (amino acids 20 to 27 of the B8R protein) of VACV is fully conserved in ECTV (48). We found that several SD determinants of VACV are also fully conserved and serve as SD determinants in ECTV. Armed with this knowledge, we immunized susceptible B6.D2-D6 mice with DCs pulsed with the ID or SD peptides. We found that this method of immunization resulted in the induction of a high frequency of memory CD8+ T cells to some but not all the peptides. B6.D2-D6 mice immunized with those peptides that successfully induced high frequencies of memory CD8+ T cells were protected from mousepox, regardless of their immunodominance hierarchy during infection. Additionally, we found that B6 mice immunized with TSYKFESV-pulsed DCs remained resistant to mousepox after NK cell depletion (10, 25, 43), suggesting that when memory CD8+ T cells are present, NK cells may no longer be required for resistance to viral diseases. Our findings are important for a thorough understanding of the mechanisms of protective T cell immunity and for the rational development of CD8+ T cell vaccines.

MATERIALS AND METHODS

Ethics statement.

All experiments were performed following guidelines of the National Institutes of Health. The Fox Chase Cancer Center (FCCC) Institutional Animal Care and Use Committee approved the experimental protocols involving animals.

Viruses.

Initial stocks of the wild-type (WT) ECTV Moscow (6, 15) were obtained from ATCC (VR-1374). New stocks of ECTV WT were expanded in BS-C-1 cells infected with 0.1 PFU/cell as described previously (57). Briefly, BS-C-1 cells in T150 flasks were infected with 0.1 PFU/cell. After 3 or 4 days cells were collected, resuspended in phosphate-buffered saline (PBS), frozen and thawed three times, and stored in aliquots at −80°C as virus stock. Virus titers in ECTV stocks were determined by plaque assays on confluent BS-C-1 cells by using 10-fold serial dilutions of the stocks in 0.5 ml Dulbecco's modified Eagle's medium (DMEM)–2.5% fetal bovine serum (FBS) in 6-well plates (2 wells/dilution) for 1 h. Two milliliters of fresh DMEM–2.5% FBS was added, and the cells were incubated at 37°C for 5 days. Next, the medium was aspirated and the cells were fixed for 1 h with 3.7% paraformaldehyde, washed with water, and stained with 0.1% crystal violet in 20% ethanol. The fix/stain solution was subsequently aspirated, the cells air dried, the plaques counted, and PFU/ml values in stocks were calculated accordingly.

For the determination of virus titers in spleens, the spleens were removed from experimental mice on the indicated days after footpad infection, made into a single-cell suspension between two frosted slides, and resuspended in 10 ml complete RPMI medium. One-milliliter aliquots of the cell suspensions were frozen and thawed three times, and titers were determined in 10-fold serial dilutions of the cell lysates as described above. Virus titers were calculated as PFU/spleen. To determine the virus titers in liver, a portion of the liver was weighed and homogenized in medium by using a tissue lyser (Qiagen). The virus titers were calculated as PFU/gram of liver.

Mice and infections.

The Fox Chase Cancer Center Institutional Animal Care and Use Committee approved the experimental protocols involving animals. C57BL/6 mice were purchased from Taconic when they were 8 to 10 weeks of age and were rested at least a week before use in experiments. The B6.D2-(D6Mit149-D6Mit15)/LusJ (B6.D2-D6) mice were initially purchased from Jackson Laboratory and bred in the Fox Chase Cancer Center Laboratory Animal Facility. Unless indicated, mice were infected with ECTV in the left footpad with 25 μl PBS containing 3 × 103 PFU. Following infections, mice were observed daily for signs of disease (lethargy, ruffled hair, weight loss, skin rash, eye secretions) and imminent death (unresponsiveness to touch, lack of voluntary movements).

In vivo cytotoxicity assays.

In vivo cytotoxicity assays were performed as described elsewhere (14). Briefly, red blood cell-depleted splenocytes from naïve B6 mice were split into two populations. One population was labeled with a high concentration of carboxyfluorescein succinimidyl-ester (CFSE) at 4 μM (CFSEhigh) and pulsed with SIINFEKL or a VACV/ECTV determinant, TSYKFESV (B8R20–27), SIFRFLNI (J3R289–296), KSYNYMLL (A3L270–277), ITYRFYLI (A8R189–196), or STLNFNNL (E7R130–137) (GenScript) at a final concentration of 1 μg/ml. For in vivo cytotoxicity assays in DC-vaccinated memory mice, the second population of lymphocytes was labeled with a low concentration of CFSE (0.8 μM; CFSElow) and was pulsed with the SIINFEKL peptide at a final concentration of 1 μg/ml. The two cell populations were mixed together in a 1:1 ratio, and 2 × 107 cells were injected i.v. into naïve or ECTV-infected B6 mice or naïve or DC-vaccinated memory mice. For naïve and ECTV-infected B6 recipient and naïve and DC-vaccinated memory mice, at 4 h and 18 h, respectively, after target cell inoculation, the recipient mice were sacrificed and the presence of CFSElow and CFSEhigh cells was determined by flow cytometry in cell suspensions of lymph nodes and spleens from individual mice. To calculate the percent specific lysis, the following formula was used: [1 − (ratio for unprimed/ratio for primed)] × 100, where the ratio for unprimed and primed were calculated as the percent CFSElow/percent CFSEhigh (21).

Histopathology.

Livers were aseptically collected, and 0.5- to 1.0-g liver sections were fixed in formalin and embedded in paraffin blocks. Serial sections were stained with hematoxyl and eosin (H&E) or immunostained with EVM135.

Bone marrow-derived dendritic cells and vaccination.

We generated bone marrow-derived CD11c+ DCs in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) as described previously (23). Lipopolysaccharide (100 ng/ml; Sigma) was added on the last day to induce maturation. After 5 to 7 days in culture, the cells were collected, incubated for 1 h with 1 μg peptide, washed extensively, and resuspended in PBS (2 × 106 cells/ml), and 500 μl was inoculated i.v. into recipient mice.

Flow cytometry.

Detection of T cell responses was performed as described previously (1214, 58). Briefly, spleens from mice were made into single-cell suspensions, and the red blood cells were lysed in 0.84% NH4Cl. Liver-infiltrating mononuclear cells were separated by centrifugation over 36% Percoll (GE Healthcare). Cells were washed, and 106 cells were cultured at 37°C in 96-well plates. For each sample, 2 × 106 cells were incubated with no peptide or 0.1 μg/ml TSYKFESV, SIFRFLNI, or SIINFEKL for restimulation in the presence of brefeldin A (BFA; Sigma) and monensin (Golgi plug; Becton, Dickinson [BD]). After 2 h, 0.4 μg of CD107a antibody (Ab; Biolegend) was added to measure degranulation. After a total of 5 h of restimulation, supernatant of Ab 2.4G2 (anti-Fcγ II/III receptor; ATCC) was added to block nonspecific binding of labeled Ab to Fc receptors. The cells were then stained for cell surface molecules, fixed, permeabilized, and stained for intracellular molecules by using the Cytofix/Cytoperm kit (BD) according to the manufacturer's instructions. The following Abs were used: anti-CD3 (145-2C11; Biolegend), anti-CD4 (GK1.5; Biolegend), anti-CD8a (53-6.7; Biolegend), anti-IFN-γ (clone XMG1.2; Biolegend), anti-CD14 (Sa14-2; Biolegend), anti-CD16 (93; Biolegend), anti-CD19 (6D5; Biolegend), anti-CD107a (1D4B; Biolegend), and phycoerythrin-Cy5.5-labeled anti-human GzB (Caltag), which cross-reacts with mouse GzB (57). For VACV/ECTV- and SIINFEKL-specific CD8+ T cells, H-2 Kb:Ig recombinant fusion protein (Dimer-X; BD) was incubated with synthetic TSYKFESV, ITYRFYLI, SIFRFLNI, KSYNYMLL, and SIINFEKL peptides and used as recommended by the manufacturer. On some occasions, instead of Kb-peptide dimers, we used Kb-TSYKFESV, -SIFRFLNI, -KSYNYMLL, and -STLNFNNL tetramers prepared by the NIAID Tetramer Facility or Kb-TSYKFESV or -SIINFEKL tetramers prepared in our laboratory according to published methods (47). Stained cells were analyzed by flow cytometry at the Fox Chase Cell Sorting Facility using an LSR II system (BD). At least 100,000 cells were analyzed.

Data display and statistical analysis.

Unless indicated, all displayed data correspond to one representative experiment of at least two similar experiments with groups of three to six mice. Spleens and livers were analyzed individually, and results are representative of at least two independent experiments. Statistical analysis was performed using GraphPad Prism software. For survival studies, P values were obtained using the log-rank (Mantel-Cox) test. All other statistical analyses were performed using an unpaired two-tailed t test or the Mann-Whitney test as necessary. When applicable, data are displayed with means ± standard error of the means (SEM). P values were determined between SIINFEKL-immunized or TSYKFESV-immunized mice and all other groups. Data were analyzed to P levels of 0.05, 0.01, and 0.001, as shown in the figures and described in the figure legends below (when not marked in the figures, the differences were not statistically significant).

RESULTS

Identification of H-2 Kb-restricted ECTV determinants.

By using intracellular staining for IFN-γ, we and others previously identified 49 determinants that account for the majority (94.8%) of the CD8+ T cell response to VACV Western Reserve (WR) in B6 mice (36, 48, 61). Of interest, the ID determinant TSYKFESV has been shown to be fully conserved and a major determinant in ECTV (36, 61). When we compared sequences, we found that the amino acids of 37 VACV SD determinants (36) were fully conserved in ECTV. At least several of these peptides were ECTV determinants, because a significant proportion of CD8+ T lymphocytes from ECTV-infected B6 mice were stained with Kb multimers loaded with the conserved VACV SD peptides SIFRFLNI, KSYNYMLL, ITYRFYLI, and STLNFNNL, albeit at a lower frequency than when loaded with TSYKFESV (Fig. 1A and andB).B). Also, 4 h after inoculation into ECTV-infected B6 mice, splenocytes pulsed with any of the SD peptides were killed significantly less than when pulsed with TSYKFESV but significantly more than when pulsed with the control SIINFEKL (Fig. 1C and andD).D). Thus, while less pronounced, probably due to the kinetics of the assay, the in vivo cytotoxicity results were consistent with those of Kb multimer staining.

Fig 1
Identification of H-2 Kb-restricted ECTV determinants. (A) B6 mice were infected with 3,000 PFU of ECTV in the footpad, and splenocytes were analyzed 7 dpi. Representative flow cytometry plots show the frequencies of CD8+ cells positive for H-2 Kb-TSYKFESV, ...

Variable responses to immunization with DCs pulsed with ECTV/VACV CD8+ T cell determinant peptides.

Mousepox-susceptible B6 congenic B6.D2-D6 mice were immunized and boosted (1 week apart) with DCs pulsed with various ECTV/VACV peptides or the control, SIINFEKL. Four weeks after boost, CD8+ T cells specific for the different peptides were identified by staining with Kb multimers loaded with the relevant peptides (Fig. 2A). Immunization with DCs pulsed with ID TSYKFESV as well as SD KSYNYMLL and SIFRFLNI, or control SIINFEKL, resulted in similarly high numbesrof Kb-peptide-specific memory CD8+ T cells. On the other hand, immunization with DCs pulsed with SD ITYRFYLI or STLNFNNL did not result in a significant increase in the frequency of cells that stained with the specific Kb-peptide complexes (Fig. 2B). When we performed in vivo cytotoxicity assays (14) in draining lymph nodes (D-LN) and spleen, there was some significant killing in mice immunized with ITYRFYLI-DC (which did not induce a significant proportion of specific memory CD8+ T cells as detected by Kb-multimer staining), but this was significantly much lower than in mice immunized with TSYKFESV-DC or SIFRFLNI-DC (Fig. 2C to toE).E). Therefore, the number of CD8+ T cells induced by peptide-pulsed DC immunization varies with the immunizing peptide, and the killing efficiency in vivo is affected by the frequency of memory CD8+ T cells that each peptide induces and by other unknown factors.

Fig 2
Variable responses to immunization with DCs pulsed with ECTV/VACV peptides. (A) Representative flow cytometry plots of the frequencies of positive Kb-TSYKFESV, -SIFRFLNI, -KSYNYML, -ITYRFYLI, -STLNFNNL, and -SIINFEKL CD8+ PBMC obtained from B6.D2-D6 mice ...

Memory CD8+ T cells elicited by immunization with peptide-pulsed DCs respond to ECTV infection.

B6.D2-D6 mice were immunized and boosted with DCs pulsed with TSYKFESV, SIFRFLNI, or SIINFEKL as a control. SD SIFRFLNI was chosen for comparison with ID TSYKFESV, because it induced comparable frequencies of Kb-peptide-specific memory CD8+ T cells (Fig. 2A and andB).B). Six to 8 weeks after boosting, the mice were infected with ECTV, and 7 days postinfection (dpi) the CD8+ T cell responses were examined in the livers (the main target organ of ECTV) and spleens (Fig. 3). Consistent with our previous finding that naive B6.D2-D6 mice do not mount CD8+ T cell responses when challenged with WT ECTV (11), none of the SIINFEKL-immunized mice mounted a TSYKFESV or SIFRFLNI CD8+ T cell response in either the spleen or the liver. On the other hand, mice immunized with DC-TSYKFESV had high frequencies and absolute numbers of CD8+ T cells that stained with Kb-TSYKFESV (Fig. 3B and andE),E), but only background numbers of cells that stained with Kb-SIFRFLNI (Fig. 3C and andF).F). In mice immunized with DC-SIFRFLNI, Kb-SIFRFLNI (Fig. 3C and andF)F) stained a high proportion and high absolute numbers of CD8+ T cells, but a relatively high number of cells also stained with Kb-TSYKFESV (Fig. 3B and andE).E). This was not due to cross-reactivity, because each cell stained with only one tetramer (Fig. 3A and andD).D). Thus, in the presence of memory cells to SD SIFRFLNI, a primary response to the ID TSYKFESV was rescued, but not vice versa. Rescue of a primary response by memory CD8+ T cells after DC immunization is consistent with our finding that adoptively transferred memory CD8+ T cells can rescue a primary response in otherwise-unresponsive B6.D2-D6 mice. This rescue of a primary response is likely due to the ability of the memory cells to lower virus loads thereby preventing the death of naïve lymphocytes (S. Remakus et al., submitted for publication).

Fig 3
Memory CD8+ T cells elicited by immunization with peptide-pulsed DCs are present in the liver and spleen after ECTV infection. B6.D2-D6 mice were immunized with peptide-DC and 2 months later infected with 3,000 PFU of ECTV in the footpad. At 7 dpi, livers ...

We also analyzed the effector CD8+ T cell responses after in vitro restimulation with peptide. TSYKFESV restimulation resulted in a significant increase in the frequency of CD8+ T cells expressing IFN-γ in liver mononuclear cells (Fig. 4A and andC)C) and splenocytes (Fig. 4B and andD)D) from DC-TSYKFESV-immunized mice. Similarly, SIFRFLNI restimulation of liver mononuclear cells (Fig. 4A and andC)C) and splenocytes (Fig. 4B and andD)D) from DC-SIFRFLNI-immunized mice resulted in a significantly increased frequency of IFN-γ+ CD8+ cells. CD8+ T cells from the livers of DC-SIINFEKL-immunized mice significantly upregulated IFN-γ expression following restimulation with SIINFEKL, albeit to low levels, likely because they did not expand (Fig. 4A and andC).C). On the other hand, SIINFEKL restimulation of splenocytes from DC-SIINFEKL-immunized mice did not result in a significant increase of IFN-γ expression in CD8+ T cells (Fig. 4B and andD),D), most likely due to the severe lymphopenia that these close-to-death mice endure. As we showed before (14), GzB expression is independent of peptide restimulation and a marker of virus-specific CD8+ T cell effectors. Accordingly, we found that DC-TSYKFESV and DC-SIFRFLNI-immunized mice had a significantly higher proportion of CD8+ T cells that expressed GzB than DC-SIINFEKL-immunized mice in both liver mononuclear cells (Fig. 4A and andE)E) and splenocytes (Fig. 4B and andF).F). The relatively low proportion of cells producing IFN-γ compared to Kb-peptide staining or GzB expression is consistent with our previous report showing that the majority of the ECTV-specific effector CD8+ T cells do not produce IFN-γ upon ex vivo restimulation (14). Together, these experiments demonstrate that mousepox-susceptible B6.D2-D6 mice immunized with DCs pulsed with ID TSYKFESV or SD SIFRFLNI, but not with irrelevant SIINFEKL, mount strong recall CD8+ T cell responses to ECTV. The results also showed that mice immunized with ID TSYKFESV do not mount a primary response to SD SIFRFLNI (Fig. 3 and and4),4), while mice immunized with SD SIFRFLNI mount a non-cross-reactive primary response to the ID TSYKFESV (Fig. 3).

Fig 4
Memory CD8+ T cells elicited by immunization with peptide-pulsed DCs become activated in the liver and spleen in response to ECTV infection. B6.D2-D6 mice were immunized with DCs pulsed with the indicated peptides and 2 months later infected with 3,000 ...

Productive peptide-DC immunization results in protective immunity against lethal mousepox.

B6.D2-D6 mice primed and boosted 6 to 8 weeks earlier with DCs pulsed with the ID TSYKFESV, SD SIFRFLNI, or ITYRFYLI (all of which induced a high frequency of memory cells, as detected by Kb-peptide staining), with SD KSYNYMLL or STLNFNNL (which did not induce a significant number of memory CD8+ T cells) or control SIINFEKL (which induced a high frequency of memory CD8+ T cells upon immunization but is not an ECTV determinant) were challenged with ECTV. All the mice immunized with DCs pulsed with ID TSYKFESV and SD SIFRFLNI survived the infection and lost <2% of their weight (Fig. 5A and andB).B). Mice immunized with KSYNYMLL-pulsed DCs were also highly protected, because 80% survived the infection and lost <10% of their weight. On the other hand, all mice immunized with DCs pulsed with ITYRFYLI or STLNFNNL (which did not generate a significant response), or with SIINFEKL, succumbed to the infection and lost ≥10% of their weight. Still, ITYRFYLI-DC immunization was somewhat protective, because death was delayed by 4 days compared with SIINFEKL immunized mice (Fig. 5A and andBB).

Fig 5
Productive peptide-DC immunization results in protective immunity against lethal mousepox infection. B6.D2-D6 mice were immunized and boosted (1 week apart) with the indicated peptide-DC dimer and challenged more than 1 month later with 3,000 PFU of ECTV ...

Next, we compared virus loads and pathology in protected versus control unprotected mice. At 7 dpi, TSYKFESV- and SIFRFLNI-immunized mice had significantly lower virus loads in the spleen and liver than did SIINFEKL-immunized mice (Fig. 5C and andD).D). Moreover, 7 dpi the livers of TSYKFESV- and SIFRFLNI-immunized mice had significantly fewer necrotic foci than SIINFEKL-immunized mice. Different from the foci in SIINFEKL-immunized mice, the few necrotic foci in TSYKFESV- or SIFRFLNI-immunized mice had a mononuclear cell infiltrate. Furthermore, at 7 dpi very few areas in the livers of TSYKFESV- or SIFRLNI-immunized mice, but most of the livers of SIINFEKL-immunized mice, were stained with antisera to the structural ECTV protein EVM135 (Fig. 5E). Thus, if productive, immunization with ID and SD ECTV peptides protects from lethal mousepox infection by controlling virus replication and liver damage.

NK cells are no longer required for resistance to mousepox following effective peptide-DC immunization.

Because the effector mechanisms of CD8+ T cells and NK cells overlap, we next tested whether NK cells are dispensable for protection when anti-ECTV memory CD8+ T cells are present. B6 mice were immunized with TSYKFESV-DC, which resulted in a significant increase in the frequency of CD8+ T cells that stained with Kb-TSYKFESV, as measured 4 weeks after booster immunization (Fig. 6A and andB).B). At 6 to 8 weeks postboost, TSYKFESV-DC-immunized and control unimmunized B6 mice were depleted of NK cells and were challenged with ECTV 1 day later. Eighty percent of TSYKFESV-DC-immunized mice survived, while all controls died (Fig. 6C). Thus, memory CD8+ T cells of single specificity significantly protected mice from lethal mousepox in the absence of NK cells.

Fig 6
Memory CD8+ T cells induced by peptide-DC immunization protect mice against lethal mousepox infection in the absence of NK cells. B6 mice were immunized with peptide-pulsed DCs. (A) Representative data for the percentage of Kb-TSYKFESV-positive CD8+ in ...

DISCUSSION

In this study, we have demonstrated that memory CD8+ T cells of single specificity induced by immunization with DCs pulsed with viral peptides protect from an acute lethal viral disease. Furthermore, we showed that CD8+ T cells directed to the ID as well as to those SD determinants that were effective at inducing a significant CD8+ T cell response upon DC-peptide immunization were highly protective. Moreover, we showed that protection can be achieved even in the absence of NK cells, which are essential for resistance to primary ECTV infection.

Other laboratories have previously studied the differential protective abilities of memory CD8+ T cells specific for single ID or SD determinants during LCMV infection (20, 28, 29, 34, 41, 44, 4951, 53, 56). However, the pathogenesis of LCMV is very different from that of ECTV. Natural LCMV infection in the mouse occurs in utero and results in a chronic infection rather than an acute disease (4). Depending on the dose, route, and clone, experimental intraperitoneal (i.p.) or i.v. infection results in transient acute or chronic infection without major symptoms and causes fatal meningitis only after intracerebral inoculation.

Somewhat analogous studies have also been performed following infection with respiratory viruses. For example, Fu et al. generated a DNA construct encoding full-length NP with two mutations (NPmut) that eliminated the ID determinant NP147-155 from influenza virus A/PR/8/34. This allowed for the detection of the immunorecessive determinant NP218-226 (19). NP218-226 behaves as a typical immunorecessive determinant in that specific CD8+ T cell response, which can be detected only when the ID determinant is absent during priming (39, 40, 42). BALB/c mice were immunized intramuscularly with NPmut DNA and were protected against cross-strain challenge with A/HK/68 (H3N2). Also, Cole et al. demonstrated that the hierarchy of CD8+ T cell determinants recognized in Sendai virus can be selectively altered by immunization against an SD determinant, with the resulting CD8+ T cell response following virus challenge directed predominantly to the subdominant determinant (8). In addition, Kast et al. showed that peptide immunization with the ID peptide of Sendai virus protected mice from a lethal challenge (27). In these experiments, protection conferred by memory CD8+ T cells specific for an SD determinant was not assessed. These studies differed from ours because, different from ECTV infection, influenza and Sendai viruses produce disease by replicating at the primary site of infection rather than by spreading systemically. Moreover, we examined protection by CD8+ T cells against subdominant rather than immunorecessive determinants, and we found that the response to the ID determinant was not abrogated in the presence of memory cells to the SD determinant.

Regarding infection with the related OPV VACV, studies of DNA vaccines containing ID or SD determinants from simian or human immunodeficiency virus showed a reduction in virus titers in ovaries of mice infected i.p. with recombinant VACV expressing the relevant determinants (24, 33). Snyder et al. showed protection against lethal secondary intranasal (i.n.) VACV challenge in HLA-A2 transgenic mice by vaccination with an MHC-I-restricted T cell determinant. However, mice with a memory CD8+ T cell response to a single determinant did not have complete protection, as some mice lost weight and some mice died. This did not occur in mice previously immunized with the whole virus (46). Cornberg et al. showed that VACV-E7R-specific memory CD8+ T cells reduced viral load in the fat pads of mice following a nonlethal dose of VACV inoculated i.p. Previously, we showed variable levels of protection against i.n. VACV challenge in mice immunized 12 days earlier with synthetic SD determinants (37). In agreement, here we also have shown that immunization against the SD epitopes KSYNYMLL and SIFRFLNI resulted in high frequencies of peptide-specific CD8+ T cells and very strong protection. On the other hand, immunization with ITYRFYLI- or STLNFNNL-pulsed DCs was not effective at inducing memory CD8+ T cells, and protection was almost nil even though their affinity for MHC-I is very high, ~6 and ~12 nM, respectively (37). Of interest, while in this study ITYRFYLI and STLNFNNL were very poor immunogens, they were immunogenic and protective against VACV in our previous report (37). At this point we can only speculate about the reasons why DC immunization failed to induce protective responses to these peptides. A major difference with the previous report is that VACV is not a natural pathogen of the mouse, replicating poorly in this host. In addition, i.n. VACV infection is mainly a local infection that produces pneumonia (31, 35), while footpad infection with ECTV causes systemic disease following lympho-hematogenous spread (4). As we have previously shown, a major mechanism whereby memory CD8+ T cells protect from mousepox is by curbing lympho-hematogenous spread. Another difference between the two studies is that here we used DC-peptide immunization and analyzed protection at 6 to 8 weeks after immunization, while in the previous report we examined protection by virus-specific CD8+ T cells at 12 days postimmunization with peptide in incomplete Freund adjuvant (IFA) and with an MHC-II helper peptide. The time of challenge and methods of immunization may have been responsible for the differences observed. For example, the challenge with ECTV was performed during the memory phase of the response, while the challenge with VACV was done when the CD8+ T cells were still effectors and when IFA inflammatory signals may have still been present at the time of challenge. It is also possible that DC immunization failed to selectively induce responses to some peptides, even though they have high affinity for MHC-I. In support, we have been unable to induce responses to the influenza virus A/PR8/34 NP immunodominant epitope ASNENMEM by DC immunization, even though it has an 8 nM affinity for Db (45). DCs have an endopeptidase activity at their plasma membrane that has been shown to degrade the Kb-restricted tyrosinase epitope YMDGTMSQV, precluding its recognition by CD8+ T cells (2). Thus, it is possible that, similar to YMDGTMSQV, peptides such as ITYRFYLI, STLNFNNL, and ASNENMETM, but not the immunogenic peptides, are unsuitable for DC immunization because they are preferentially degraded at the surface of DCs. Another possibility is that, despite their high affinity for MHC-I, the half-lives of the peptide–MHC-I complexes at the surface of cells is shorter for the nonimmunogenic than the immunogenic peptides. As an example, the half-life of Db-ASNENMETM at the cell surface is 6 h 15 min, quite shorter than that of TGICNQNII (9 h 30 min), another high-affinity NP peptide (45).

While normally resistant to footpad infection, B6 mice infected with ECTV i.n. succumb with respiratory complications. Relevant to our studies, Tscharke et al. reported that B6 mice immunized with splenic DCs pulsed with TSYKFESV were partially protected from i.n. challenge with ECTV (48). Those authors suggested that the lack of complete protection could have been due to insufficient numbers of TSYKFESV-specific CD8+ T cells induced by their method of immunization, and they indicated that there may have been at least ~50-fold fewer TSYKFESV-specific CD8+ T cells than with VACV infection. In support of this view, our prime-boost method of immunization resulted in strong responses to some but not all the peptides. We observed complete protection only when the frequency of memory CD8+ T cells was high. In agreement with our findings, West et al. demonstrated that a high frequency (105) of virus-specific memory CD8+ T cells from P14 transgenic mice were able to rapidly reduce or clear LCMV clone 13 virus (55). Thus, independent of the reason for the inability of ITYRFYLI- and STLNFNNL-pulsed DCs to induce a response, our data suggest that protection strongly correlates with productive immunization and that the immunogenicity of a peptide may vary with the method of immunization. Hence, when designing vaccines, it is important to determine the efficiency of CD8+ T cell induction by the different determinants with the specific immunization method.

Different from any of the other studies, we also analyzed the primary CD8+ T cell responses to the ID and SD determinants in mice with preexisting memory CD8+ T cells specific for the ID or an SD determinant. Interestingly, the SIFRFLNI SD response was undetectable in mice immune to the ID TSYKFESV. However, the presence of memory CD8+ T cells to SD SIFRFLNI did not override the ID response to TSYKFESV, suggesting that these primary effectors could contribute to the protection.

We previously showed that NK cells migrate to the D-LN of ECTV-infected mice and use perforin and IFN-γ-dependent mechanisms to reduce virus spread (10). We have more recently shown that B6.D2-D6 mice are susceptible to mousepox because they lack CD94, resulting in deficient control of ECTV by NK cells (11). Our finding that memory CD8+ T cells protect B6.D2-D6 from mousepox provided a first line of evidence that NK cells may no longer be required for resistance to mousepox when memory CD8+ T cells are present. However, a final conclusion could not be drawn because in B6.D2-D6, NK cells still migrate to the D-LN and produce IFN-γ following ECTV infection (11). Thus, our results showing that B6 mice immunized with DC-TSYKFESV remain resistant to mousepox after NK cell depletion definitively demonstrate that NK cells are not required when protective memory CD8+ T cells are present.

In summary, our study provides us with a better understanding of the mechanisms of acquired protection to highly infectious OPV. In addition, because ECTV spreads through the lympho-hematogenous route, our findings may be relevant for the many unrelated viruses that spread via this route (17, 52). Moreover, our work contributes to the efforts of rational vaccine development by providing information about mechanisms of acquired protection that may be applicable to other pathogenic viruses that cause acute or chronic viral diseases.

ACKNOWLEDGMENTS

We thank the Fox Chase Cancer Center Laboratory Animal, Flow Cytometry, and Tissue Culture Facilities for their services and the NIAID Tetramer Core Facility for Kb-TSYKFESV, -SIFRFLNI, -KSYNYMLL, and -STLNFNNL tetramers. We also thank Holly Gillin for assistance in the preparation of the manuscript, Andres Klein-Szanto for histopathology evaluation, and Laurence Eisenlohr for critical reading of the manuscript.

This work was supported by grants R01AI048849 and 5U19AI083008 to L.J.S. and P30CA006927 to FCCC. S.R. was partially supported by T32 CA-009035036 to FCCC.

Footnotes

Published ahead of print 27 June 2012

REFERENCES

1. Abbas AK. 1989. Antigen presentation by B lymphocytes: mechanisms and functional significance. Semin. Immunol. 1:5–12. [PubMed]
2. Amoscato AA, Prenovitz DA, Lotze MT. 1998. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. 161:4023–4032. [PubMed]
3. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT. 2005. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11:748–756. [PubMed]
4. Baker DG. 1998. Natural pathogens of laboratory mice, rats, and rabbits and their effects on research. Clin. Microbiol. Rev. 11:231–266. [PMC free article] [PubMed]
5. Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ. 2007. Apoptosis induced by the lymphocyte effector molecule perforin. Curr. Opin. Immunol. 19:339–347. [PubMed]
6. Chen W, Drillien R, Spehner D, Buller RM. 1992. Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene. Virology 187:433–442. [PubMed]
7. Chowdhury D, Lieberman J. 2008. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu. Rev. Immunol. 26:389–420. [PMC free article] [PubMed]
8. Cole GA, Hogg TL, Coppola MA, Woodland DL. 1997. Efficient priming of CD8+ memory T cells specific for a subdominant epitope following Sendai virus infection. J. Immunol. 158:4301–4309. [PubMed]
9. Delano ML, Brownstein DG. 1995. Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J. Virol. 69:5875–5877. [PMC free article] [PubMed]
10. Fang M, Lanier LL, Sigal LJ. 2008. A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog. 4:e30 doi:10.1371/journal.ppat.0040030. [PMC free article] [PubMed]
11. Fang M, et al. 2011. CD94 is essential for NK cell-mediated resistance to a lethal viral disease. Immunity 34:579–589. [PMC free article] [PubMed]
12. Fang M, Sigal L. 2010. Studying NK cell responses to ectromelia virus infections in mice. Methods Mol. Biol. 612:411–428. [PubMed]
13. Fang M, Sigal LJ. 2005. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J. Immunol. 175:6829–6836. [PubMed]
14. Fang M, Sigal LJ. 2006. Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host. J. Immunol. 177:8027–8036. [PubMed]
15. Fenner F. 1949. Mouse-pox: infectious ectromelia of mice. A review. J. Immunol. 63:341–373. [PubMed]
16. Fenner F, et al. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
17. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. 2009. Principles of virology, 3rd ed ASM Press, Washington, DC.
18. French AR, Yokoyama WM. 2003. Natural killer cells and viral infections. Curr. Opin. Immunol. 15:45–51. [PubMed]
19. Fu TM, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. 1997. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 71:2715–2721. [PMC free article] [PubMed]
20. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187:1647–1657. [PMC free article] [PubMed]
21. Ge Q, Bai A, Jones B, Eisen HN, Chen J. 2004. Competition for self-peptide-MHC complexes and cytokines between naive and memory CD8+ T cells expressing the same or different T cell receptors. Proc. Natl. Acad. Sci. U. S. A. 101:3041–3046. [PubMed]
22. Guidotti LG, Chisari FV. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19:65–91. [PubMed]
23. Hamilton SE, Porter BB, Messingham KA, Badovinac VP, Harty JT. 2004. MHC class Ia-restricted memory T cells inhibit expansion of a nonprotective MHC class Ib (H2-M3)-restricted memory response. Nat. Immunol. 5:159–168. [PubMed]
24. Im EJ, et al. 2011. Protective efficacy of serially up-ranked subdominant CD8 T cell epitopes against virus challenges. PLoS Pathog. 7:e1002041 doi:10.1371/journal.ppat.1002041. [PMC free article] [PubMed]
25. Jacoby RO, Bhatt PN, Brownstein DG. 1989. Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus. Arch. Virol. 108:49–58. [PubMed]
26. Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J. 1996. Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J. Virol. 70:8301–8309. [PMC free article] [PubMed]
27. Kast WM, et al. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. U. S. A. 88:2283–2287. [PubMed]
28. Klavinskis LS, Whitton JL, Joly E, Oldstone MB. 1990. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology 178:393–400. [PubMed]
29. Klavinskis LS, Whitton JL, Oldstone MB. 1989. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J. Virol. 63:4311–4316. [PMC free article] [PubMed]
30. Lanier LL. 1998. NK cell receptors. Annu. Rev. Immunol. 16:359–393. [PubMed]
31. Law M, Putz MM, Smith GL. 2005. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J. Gen. Virol. 86:991–1000. [PubMed]
32. Lieberman J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol. 3:361–370. [PubMed]
33. Liu J, et al. 2006. Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J. Virol. 80:11991–11997. [PMC free article] [PubMed]
34. Martins LP, Lau LL, Asano MS, Ahmed R. 1995. DNA vaccination against persistent viral infection. J. Virol. 69:2574–2582. [PMC free article] [PubMed]
35. Montasir M, Rabin ER, Phillips CA. 1966. Vaccinia pneumonia in mice. A light and electron microscopic and viral assay study. Am. J. Pathol. 48:877–895. [PubMed]
36. Moutaftsi M, et al. 2006. A consensus epitope prediction approach identifies the breadth of murine T (CD8+)-cell responses to vaccinia virus. Nat. Biotechnol. 24:817–819. [PubMed]
37. Moutaftsi M, et al. 2009. Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur. J. Immunol. 39:717–722. [PMC free article] [PubMed]
38. Murali-Krishna K, et al. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177–187. [PubMed]
39. Mylin LM, Bonneau RH, Lippolis JD, Tevethia SS. 1995. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69:6665–6677. [PMC free article] [PubMed]
40. Oldstone MB, Lewicki H, Borrow P, Hudrisier D, Gairin JE. 1995. Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J. Virol. 69:7423–7429. [PMC free article] [PubMed]
41. Oldstone MB, et al. 1993. Vaccination to prevent persistent viral infection. J. Virol. 67:4372–4378. [PMC free article] [PubMed]
42. Oukka M, Riche N, Kosmatopoulos K. 1994. A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells. J. Immunol. 152:4843–4851. [PubMed]
43. Parker AK, Parker S, Yokoyama WM, Corbett JA, Buller RM. 2007. Induction of natural killer cell responses by ectromelia virus controls infection. J. Virol. 81:4070–4079. [PMC free article] [PubMed]
44. Rodriguez F, Slifka MK, Harkins S, Whitton JL. 2001. Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities. J. Virol. 75:7399–7409. [PMC free article] [PubMed]
45. Sigal LJ, Goebel P, Wylie DE. 1995. Db-binding peptides from influenza virus: effect of non-anchor residues on stability and immunodominance. Mol. Immunol. 32:623–632. [PubMed]
46. Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA. 2004. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78:7052–7060. [PMC free article] [PubMed]
47. Toebes M, Rodenko B, Ovaa H, Schumacher TN. 2009. Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr. Protoc. Immunol. Chapter 18:Unit 18.16. [PubMed]
48. Tscharke DC, et al. 2005. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201:95–104. [PMC free article] [PubMed]
49. van der Most RG, et al. 1997. Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. J. Virol. 71:5110–5114. [PMC free article] [PubMed]
50. van der Most RG, et al. 1998. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology 240:158–167. [PubMed]
51. van der Most RG, et al. 1996. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J. Immunol. 157:5543–5554. [PubMed]
52. Virgin HW. 2007. Pathogenesis of viral infection, p 335–336 In Fields BN, Knipe DM, Howley PM, editors. (ed), Fields virology, 5th ed, vol 1 Lippincott Williams & Wilkins, Philadelphia, PA.
53. von Herrath MG, Dockter J, Nerenberg M, Gairin JE, Oldstone MB. 1994. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J. Exp. Med. 180:1901–1910. [PMC free article] [PubMed]
54. Wallace GD, Buller RM, Morse HC., III 1985. Genetic determinants of resistance to ectromelia (mousepox) virus-induced mortality. J. Virol. 55:890–891. [PMC free article] [PubMed]
55. West EE, et al. 2011. Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity 35:285–298. [PMC free article] [PubMed]
56. Whitton JL, Sheng N, Oldstone MB, McKee TA. 1993. A “string-of-beads” vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J. Virol. 67:348–352. [PMC free article] [PubMed]
57. Wolint P, Betts MR, Koup RA, Oxenius A. 2004. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J. Exp. Med. 199:925–936. [PMC free article] [PubMed]
58. Xu RH, Fang M, Klein-Szanto A, Sigal LJ. 2007. Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection. Proc. Natl. Acad. Sci. U. S. A. 104:10992–10997. [PubMed]
59. Yewdell JW. 2006. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25:533–543. [PubMed]
60. Yewdell JW, Bennink JR. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:51–88. [PubMed]
61. Yuen TJ, et al. 2010. Analysis of A47, an immunoprevalent protein of vaccinia virus, leads to a reevaluation of the total antiviral CD8+ T cell response. J. Virol. 84:10220–10229. [PMC free article] [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)